Medicines affordability in the US
Some people with diabetes in the US are increasingly finding it hard
to pay for their medicines, especially those uninsured and in
high-deductible healthcare plans. This is not acceptable.
In line with our social responsibility, we have launched initiatives
and programmes offering people living with diabetes in the US insulin
affordability options. These include:
- Providing a , which in 2018
provided free insulin to nearly 50,000 people with diabetes. Through
the programme, an individual with an annual income up to 49,960 US
dollars, and a family of four with a combined annual income up to
103,000 US dollars, may qualify for free Novo Nordisk medicines -
including all of our insulin products.
- Making low-cost
human insulin available at . This offering
has been in place for almost two decades and has recently been made
available in other national pharmacy chains through programmes with
CVS and ESI. Around 500,000 Americans are using our human insulin
through these partnerships.
- Through our offering, all eligible patients
can purchase up to three vials or two packs of
of any combination of insulins from Novo Nordisk Inc. for $99 with a
- Offering to help defray
out-of-pocket costs for commercially-insured patients.
available for people facing an acute need when more time is needed
to identify a long-term sustainable solution.
- Making of two of our modern
insulins from new Novo Nordisk A/S US company, Novo Nordisk Pharma,
Inc., available at pharmacies within 1-3 business days at 50 percent
off the list price.
The complexity of the US healthcare system means that arriving at
solutions that ensure affordable access to medicines for all is not
straightforward. However, we believe that with collaboration across
all parties in the system, sustainable solutions can be
We want to be part of a solution and we are actively working with
stakeholders across the US healthcare system to find ways that help
reduce the burden on patients both in the short-term and for
Find out more
about NovoCare® and our insulin affordability initiatives in the US